Abstract
Measles is an acute highly infectious viral disease. Although live attenuated vaccine is used throughout the world, outbreaks of disease still occur in many countries including Iran. In this cross-sectional study, by implementing a viral neutralization test and cell culture techniques, the seroprevalence of neutralizing anti-measles antibodies was assessed. Three hundred and fifty-four blood samples were collected and random-cluster classified from healthy subjects 6 months to 16 years old, residing in the town of Khodabandeh and its rural areas. Of the total subjects, 174 (49.2%) were girls and 180 (50.8%) were boys. From 354 subjects studied, 310 (87.6%) had neutralizing anti-measles antibody titer of 1:8 or higher and were considered to be immune and 44 (12.4%) had lower antibody titers. At the time of specimen collection, information with regards to age, sex, history of vaccination and place of residence were collected. χ 2 statistical test demonstrated a significant association between immune status and grouped age at the time of first vaccination (p < 0.009). The proportion test indicated significant differences in rate of seropositivity in paired age groups (3–8 vs. 9–11 and 9–11 vs. 12–64 months) (p < 0.02). The use of reliable techniques for assessing success of vaccination programs and performing seroepidemiological studies in order to organize national programs of control and eradication of measles are necessary.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cox MJ, Azevedo RS, Massad E, et al. Measles antibody level in a vaccinated population in Brazil. Trans R S Trop Med Hygiene 1998; 92: 227–230.
Grandolfo ME, Medda E, Novello F, et al. Seroepidemiological evaluation of 1989-1991 mass vaccination campaigns against measles in Italy. Epidemiol Infect 1998; 121: 645–652.
Aaby P, Knudsen K, Jensen TG, et al. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis 1990; 162: 1043–1048.
Matter L, German D, Bally F, et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur J Epidemiol 1997; 13: 61–66.
Babad HR, Nokes DJ, Gay NJ, et al. Predicting the impact of measles vaccination in England and Wales: Mode 1 validation and analysis of policy options. Epidemiol Infect 1995; 114: 319–344.
Redd SC, Markowitz LE, Katz SL. Measles Vaccine. In: Plotkin and Orenstein's Vaccines, 3rd ed. Philadelphia: W.B. Saunders Company, 1999: 222–265.
Reports of epidemiological studies in Iran, years 1996, 1997 and 1998. National Institute for Prevention and Control of Diseases, Ministry of Health and Health Education of Iran.
Mokhtari-Azad T, Naghavi M, Hassan Negad Q, Nategh R. Assessment of immune status against measles in relation with vaccination history in children 7-11 years old in town of Ray in 1992. J Med School Tehran Univ 1994; 52(3-4): 41–49.
Lennette EH. Diagnosis Procedure for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington DC: American Public Health Association, 1995.
Ballew HC. Neutralization. In: Clinical Virology Manual, 2nd ed. New York: Elsevier, 1992; 229–242.
Kalter SS, Herberling RL, Barry JD, et al. Detection and titration of measles virus antibody by hemagglutination inhibition and by dot immunobinding. J Clin Microbiol 1991; 29(1): 202–204.
Neumann PW, Weber JM, Jessamine AG, et al. Comparison of measles antihemolysin test, enzymelinked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 1985; 22(2): 296–298.
Lee MS, et al. Seroepidemiology and evaluation of passive surveillance during 1988-1989 measles outbreak in Taiwan. Int J Epidemiol 1992; 21(6): 1165–1174.
Cutts FT, Lauri E, Markowitz E. Successes and failures in measles control. J Infect Dis 1994; 170(Suppl. 1): S32–41.
Daie Parizi MH, Janghorbani M, Ghorbani K. Measles epidemics in Kerman, Iran. Med J Islamic Republic Iran 1993; 6(4): 249–254.
Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants 6, 9, and 12 months. J Infect Dis 2001; 184: 817–826.
Hutchins SS, Redd SC, Schrag S, et al. Evaluation of an early two-dose 1 measles vaccination schedule. Am J Epidemiol 2001; 154: 1064–1071.
Bautista-Lopez N, Ward BJ, Mills E, et al. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000; 18: 1393–1401.
Griffin DE, Ward BJ, Esolen LM, et al. Pathogenesis of measles virus infection: A hypothesis for altered immune response. J Infect Dis 1994; 170(1): 524–531.
Griffin DE, Bellini WJ. Measles Virus. In: Field's Virology, 3rd ed. New York: Raven Press, 1996; 1267–1313.
Lee MS, Cohen B, Hand J, Nokes J. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Meth 1999; 78: 209–217.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Khodabandeh Loo, M., Sabahi, F., Soleimanjdahi, H. et al. Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998. Eur J Epidemiol 18, 1085–1089 (2003). https://doi.org/10.1023/A:1026104522780
Issue Date:
DOI: https://doi.org/10.1023/A:1026104522780